



(11) **EP 2 142 544 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
03.07.2013 Bulletin 2013/27

(45) Date of publication and mention
of the grant of the patent:
22.05.2013 Bulletin 2013/21

(21) Application number: **08742864.5**

(22) Date of filing: **11.04.2008**

(51) Int Cl.:
C07D 471/04 ^(2006.01) **A61K 31/519** ^(2006.01)
A61P 35/00 ^(2006.01)

(86) International application number:
PCT/US2008/004807

(87) International publication number:
WO 2008/127712 (23.10.2008 Gazette 2008/43)

(54) **PYRIDO [2, 3-D]PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF PI3K-ALPHA FOR THE TREATMENT OF CANCER**

PYRIDO [2,3-D]PYRIMIDIN-7-ONVERBINDUNGEN ALS INHIBITOREN VON PI3K-ALPHA ZUR BEHANDLUNG VON KREBS

COMPOSÉS PYRIDO [2, 3-D]PYRIMIDIN-7-ONE UTILISÉS EN TANT QU'INHIBITEURS DE PI3K-ALPHA POUR LE TRAITEMENT DU CANCER

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT
RO SE SI SK TR**
Designated Extension States:
AL BA MK RS

(30) Priority: **11.04.2007 US 911160 P**

(43) Date of publication of application:
13.01.2010 Bulletin 2010/02

(73) Proprietor: **Exelixis, Inc.**
South San Francisco, CA 94080 (US)

(72) Inventors:
• **BUHR, Chris A.**
Redwood City, California 94061 (US)
• **WANG, Longcheng**
Palo Alto, California 94306 (US)

(74) Representative: **Main, Malcolm Charles**
Murgitroyd & Company
Immeuble Atlantis
55 Allee Pierre Ziller
06560 Valbonne - Sophia Antipolis (FR)

(56) References cited:
WO-A-96/34867 WO-A-2005/105801
WO-A-2008/021389 WO-A1-2007/044698
WO-A1-2008/032162

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 142 544 B8